XtalPi (HKG:2228) recorded an attributable profit of 82.8 million yuan in the first half of 2025, compared with an attributable loss of 1.24 billion yuan a year prior, a Wednesday filing with the Hong Kong bourse said.
Earnings per share stood at 0.0146 yuan in the six months, while the pharma research firm had incurred a loss per share of 1.6965 yuan in the corresponding period of the last year.
Revenue rose 404% to 517.1 million yuan in the half year from 102.6 million yuan in the year-ago period.